Concepedia

Timothy J. Guzi

TJ

Statistics

Publications

24

Citations

2.6K

H-Index

19

Active since

1998

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Blueprint Medicines (United States)

Rensselaer Polytechnic Institute

LabCorp (United States)

Timothy J. Guzi is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

1998–2022

24

Publications

24

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

David Parry, Timothy J. Guzi, Nicole R. Davis et al. · Molecular Cancer Therapeutics · 2010 · 553 citations · Full text

, , +16

Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers

Vivek Subbiah, Justin F. Gainor, Rami Rahal et al. · Cancer Discovery · 2018 · 386 citations

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Margit Hagel, Chandra Miduturu, Michael P. Sheets et al. · Cancer Discovery · 2015 · 305 citations · Full text

A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutations

Erica N Evans, Alexandra K. Gardino, Joseph L. Kim et al. · Science Translational Medicine · 2017 · 209 citations

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

Kamil Paruch, Michael P. Dwyer, Carmen Álvarez et al. · ACS Medicinal Chemistry Letters · 2010 · 174 citations · Full text

, , +21

Rows per page

1–5 of 24